Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Anetumab ravtansine by Bayer for Metastatic Pancreatic Cancer: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Anetumab ravtansine by Bayer for Endometrial Cancer: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
Anetumab ravtansine by Bayer for Uterine Cancer: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Uterine Cancer. According to GlobalData, Phase...
Anetumab ravtansine by Bayer for Fallopian Tube Cancer: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
Anetumab ravtansine by Bayer for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to...
Anetumab ravtansine by Bayer for Peritoneal Cancer: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...
Anetumab ravtansine by Bayer for Epithelial Ovarian Cancer: Likelihood of Approval
Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...